Laidlaw & Company is a well-known investment bank and wealth management service on Wall Street that assists many organizations and households in the United States and in the United Kingdom.

Laidlaw & Company is SEC registered and has been helping companies reach their goals by guiding these companies to “quickly raise capital” with the support from Laidlaw & Company’s “strong retail sales force.” With this assistance, companies are able to reach their financial goals and allow the companies to expand their business.

Laidlaw has a deep history that goes all the way back to 1842, where Devid Heran and James Lees started the Heran & Lees, which eventually became Laidlaw & Co. in 1873 after Henry Bell Laidlaw became the leader of the firm.

Currently, Matthew D. Eitner is the Chief Executive Officer of Laidlaw & Company. Members of the executive office that are helping Eitner are James P. Ahern, Craig Bonn, Patrick Joseph Gallagher MBA, CFA, and Bryan Kobel.

However, the company has faced some controversy as Relmada Therapeutics, Inc. filed a complaint against Laidlaw & Company. Relmada Therapeutics is asking for the financial loss that was believed to be caused by Laidlaw & Company’s “false and misleading proxy materials in December 2015.” Also, Laidlaw is accused of disclosing “confidential information” that’s crucial to Relmada Therapeutics. This case will be handled in the United States District Court for the District of Nevada.